These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 33096752)
1. Toward G-Quadruplex-Based Anticancer Agents: Biophysical and Biological Studies of Novel AS1411 Derivatives. Ogloblina AM; Iaccarino N; Capasso D; Di Gaetano S; Garzarella EU; Dolinnaya NG; Yakubovskaya MG; Pagano B; Amato J; Randazzo A Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096752 [TBL] [Abstract][Full Text] [Related]
2. Aptamer-based Targeted Delivery of a G-quadruplex Ligand in Cervical Cancer Cells. Carvalho J; Paiva A; Cabral Campello MP; Paulo A; Mergny JL; Salgado GF; Queiroz JA; Cruz C Sci Rep; 2019 May; 9(1):7945. PubMed ID: 31138870 [TBL] [Abstract][Full Text] [Related]
3. Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation. Reyes-Reyes EM; Šalipur FR; Shams M; Forsthoefel MK; Bates PJ Mol Oncol; 2015 Aug; 9(7):1392-405. PubMed ID: 25911416 [TBL] [Abstract][Full Text] [Related]
4. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms. Bates PJ; Reyes-Reyes EM; Malik MT; Murphy EM; O'Toole MG; Trent JO Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt B):1414-1428. PubMed ID: 28007579 [TBL] [Abstract][Full Text] [Related]
5. AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. Girvan AC; Teng Y; Casson LK; Thomas SD; Jüliger S; Ball MW; Klein JB; Pierce WM; Barve SS; Bates PJ Mol Cancer Ther; 2006 Jul; 5(7):1790-9. PubMed ID: 16891465 [TBL] [Abstract][Full Text] [Related]
6. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Bates PJ; Laber DA; Miller DM; Thomas SD; Trent JO Exp Mol Pathol; 2009 Jun; 86(3):151-64. PubMed ID: 19454272 [TBL] [Abstract][Full Text] [Related]
7. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Reyes-Reyes EM; Teng Y; Bates PJ Cancer Res; 2010 Nov; 70(21):8617-29. PubMed ID: 20861190 [TBL] [Abstract][Full Text] [Related]
8. Bioactivity of 2'-deoxyinosine-incorporated aptamer AS1411. Fan X; Sun L; Wu Y; Zhang L; Yang Z Sci Rep; 2016 May; 6():25799. PubMed ID: 27194215 [TBL] [Abstract][Full Text] [Related]
9. Exploring the conformational behaviour and aggregation properties of lipid-conjugated AS1411 aptamers. Riccardi C; Musumeci D; Russo Krauss I; Piccolo M; Irace C; Paduano L; Montesarchio D Int J Biol Macromol; 2018 Oct; 118(Pt B):1384-1399. PubMed ID: 30170359 [TBL] [Abstract][Full Text] [Related]
10. Study of the Function of G-Rich Aptamers Selected for Lung Adenocarcinoma. Hu J; Zhao Z; Liu Q; Ye M; Hu B; Wang J; Tan W Chem Asian J; 2015 Jul; 10(7):1519-25. PubMed ID: 25864879 [TBL] [Abstract][Full Text] [Related]
11. AS1411 derivatives as carriers of G-quadruplex ligands for cervical cancer cells. Figueiredo J; Lopes-Nunes J; Carvalho J; Antunes F; Ribeiro M; Campello MPC; Paulo A; Paiva A; Salgado GF; Queiroz JA; Mergny JL; Cruz C Int J Pharm; 2019 Sep; 568():118511. PubMed ID: 31301466 [TBL] [Abstract][Full Text] [Related]
12. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells. Soundararajan S; Wang L; Sridharan V; Chen W; Courtenay-Luck N; Jones D; Spicer EK; Fernandes DJ Mol Pharmacol; 2009 Nov; 76(5):984-91. PubMed ID: 19657047 [TBL] [Abstract][Full Text] [Related]
14. Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells. Mosafer J; Mokhtarzadeh A Curr Drug Deliv; 2018; 15(9):1323-1329. PubMed ID: 30039760 [TBL] [Abstract][Full Text] [Related]
16. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Soundararajan S; Chen W; Spicer EK; Courtenay-Luck N; Fernandes DJ Cancer Res; 2008 Apr; 68(7):2358-65. PubMed ID: 18381443 [TBL] [Abstract][Full Text] [Related]
17. Bifunctional G-Quadruplex Aptamer Targeting Nucleolin and Topoisomerase 1: Antiproliferative Activity and Synergistic Effect of Conjugated Drugs. Jo J; Bae S; Jeon J; Youn H; Lee G; Ban C Bioconjug Chem; 2023 Jan; 34(1):238-247. PubMed ID: 36516871 [TBL] [Abstract][Full Text] [Related]
18. Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release. Ma Y; Xie D; Chen Z; Shen X; Wu X; Ding F; Ding S; Pan Y; Li F; Lu A; Zhang G J Transl Med; 2024 Jul; 22(1):604. PubMed ID: 38951906 [TBL] [Abstract][Full Text] [Related]
19. AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin. Cheng Y; Zhao G; Zhang S; Nigim F; Zhou G; Yu Z; Song Y; Chen Y; Li Y PLoS One; 2016; 11(12):e0167094. PubMed ID: 27907160 [TBL] [Abstract][Full Text] [Related]
20. Nucleolin Overexpression Confers Increased Sensitivity to the Anti-Nucleolin Aptamer, AS1411. Sharma VR; Thomas SD; Miller DM; Rezzoug F Cancer Invest; 2018; 36(9-10):475-491. PubMed ID: 30396283 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]